Does Sublocade Have a Blocker? Understanding Buprenorphine’s Opioid-Blocking Properties
Does Sublocade have a blocker? This question often arises when comparing opioid addiction treatments. Sublocade contains only buprenorphine and does not include naloxone, yet it blocks other opioids. Buprenorphine itself acts as the blocking agent by attaching to opioid receptors in your brain. Understanding if Sublocade is an opioid clarifies this mechanism—it’s a partial opioid agonist that works differently than full opioids. How Sublocade works involves blocking the reward sensation of opioids while preventing withdrawal symptoms. This guide gets into Sublocade’s opioid-blocking properties, how buprenorphine functions as a blocker, and what this means for your recovery experience.
What is Sublocade and What Does It Contain?
Sublocade represents an extended-release injectable formulation designed to treat moderate to severe opioid use disorder in adults. Approved by the FDA, this prescription medication requires patients to have already started treatment with a transmucosal buprenorphine product for a minimum of seven days before transitioning to the monthly injection. The medication serves as part of a complete treatment program that has counseling and psychosocial support.
Sublocade’s Active Ingredient: Buprenorphine
Buprenorphine functions as the sole active pharmaceutical ingredient in Sublocade. The medication delivers this ingredient through a proprietary delivery system called ATRIGEL, which consists of a biodegradable 50:50 poly(DL-lactide-co-glycolide) polymer combined with N-methyl-2-pyrrolidone (NMP), a biocompatible solvent. This liquid formulation contacts body fluids and transforms into a solid depot after subcutaneous injection into body tissue. Buprenorphine then releases over approximately one month through diffusion and biodegradation of the depot.
Sublocade comes in two dosage strengths: 100 mg delivered in 0.5 mL and 300 mg delivered in 1.5 mL. The recommended treatment protocol has two original monthly doses of 300 mg, followed by 100 mg monthly maintenance doses. The maintenance dose may remain at 300 mg monthly for certain patients where benefits outweigh risks. The 300 mg dose provides higher steady-state buprenorphine plasma levels around 5-6 ng/mL that some patients require depending on their clinical condition.
Is Sublocade an Opioid?
Buprenorphine qualifies as an opioid medication and is classified as a partial opioid agonist. Developed in the late 1960s as an analog of thebaine (an alkaloid from the poppy flower), this synthetic compound attaches to mu-opioid receptors in your brain. The Drug Enforcement Administration categorizes Sublocade as a Schedule III controlled substance, which indicates moderate-to-low potential for physical dependence or high potential for psychological dependence. Buprenorphine can be abused like other opioids, which explains why Sublocade is only accessible through a restricted program called the SUBLOCADE REMS Program.
The partial agonist designation means buprenorphine activates mu-opioid receptors partially rather than stimulating them fully like heroin or morphine. This characteristic creates several important properties that include plateauing analgesic effects at higher doses and ceiling effects on respiratory depression. Such properties make buprenorphine safer than full agonists for addiction treatment.
Why Sublocade Does Not Contain Naloxone
Sublocade’s formulation excludes naloxone. Oral buprenorphine products like Suboxone combine buprenorphine with naloxone in a 4:1 ratio to discourage misuse through injection. Naloxone serves as an opioid antagonist that reverses or blocks opioid effects and is added to sublingual formulations as an abuse deterrent.
Several factors eliminate the need for naloxone in Sublocade. Healthcare professionals administer the medication subcutaneously in clinical settings, which removes opportunities for patient misuse. Its extended-release design provides month-long medication delivery and minimizes diversion risks associated with daily dosing. The subcutaneous injection method delivers medication between skin and muscle in the abdominal region, making intravenous misuse impractical. Healthcare providers authorized through the REMS program administer Sublocade and ensure proper delivery protocols. Naloxone, if present and active in the formulation, would counteract buprenorphine’s therapeutic effects by preventing attachment to opioid receptors needed to reduce cravings and treat opioid use disorder.
How Does Sublocade Work in the Brain?
Buprenorphine’s mechanism in your brain operates through complex interactions with opioid receptors that distinguish it from traditional pain medications and illicit substances. These interactions are the foundations for understanding how does Sublocade work to treat opioid use disorder.
Buprenorphine as a Partial Opioid Agonist
Buprenorphine partially activates mu-opioid receptors while acting as a weak kappa receptor antagonist and delta receptor agonist. This partial agonism at the mu receptor creates distinctive characteristics that separate it from medications like methadone or morphine. The drug’s analgesic effects plateau at higher doses, where its effects transition into an antagonistic mode.
The partial agonist properties produce a ceiling effect. This means increasing doses do not generate the same subjective or physiologic effects as increasing doses of full agonists. Buprenorphine relieves drug cravings without producing euphoric effects associated with full opioid agonists and carries a lower overdose risk. This ceiling effect extends to respiratory depression, which means better safety compared to methadone in addiction treatment contexts.
Binding to Opioid Receptors in the Brain
Buprenorphine exhibits high-affinity binding to mu-opioid receptors with slow-dissociation kinetics. A comparative study revealed buprenorphine possessed the second highest binding affinity with a Ki of 0.2157 nM. The medication showed 120 times higher affinity compared to oxycodone, 15.6 times higher than methadone, 6.2 times higher than fentanyl, and 5.4 times higher than morphine.
This strong binding affinity causes buprenorphine to displace full agonist opioids from receptors when administered together. Buprenorphine resists displacement by other opioids once bound. The dissociation half-life ranges between 200 minutes to over 23 hours depending on conditions. This slow dissociation pattern does not occur with delta or kappa opioid receptors, in contrast with its mu-receptor binding.
The slow dissociation contributes to prolonged clinical effects and limited physical dependence indicators. Buprenorphine activates opioid receptors without achieving the same extent of activation as full agonists. Buprenorphine activates mu receptor-dependent signaling and produces analgesia when receptor density at cell surfaces is high.
The Difference Between Full Agonists and Partial Agonists
Full agonists bind tightly to opioid receptors and undergo conformational changes that produce maximal effects. Examples include codeine, fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone. These medications stabilize receptors in active forms and lead to maximum biological responses.
Partial agonists cause less conformational change and receptor activation than full agonists. The maximum effect remains unachieved when all receptors are bound by partial agonists. Partial agonists function as antagonists by competing for binding sites when full agonists are present. Buprenorphine’s partial agonism means it cannot reach maximal response capability even at full receptor occupancy. Both full and partial agonists produce similar effects at lower doses in opioid-naive individuals, but partial agonist effects plateau with dose increases.
Does Sublocade Block Other Opioids?
The blocking properties of Sublocade stem directly from buprenorphine’s unique receptor interactions. Buprenorphine occupies opioid receptors in your brain after you receive Sublocade and prevents other opioids from producing their typical effects.
How Buprenorphine Blocks Opioid Receptors
Buprenorphine displaces full agonist opioids from mu receptors through competitive binding. Its higher affinity for these receptors means full agonists cannot displace it, so it blocks their knowing how to exert opioid effects on receptors already occupied by buprenorphine. This displacement mechanism works in a dose-responsive manner. Higher doses provide stronger blockade effects.
Research indicates that approximately 50% to 60% buprenorphine receptor occupancy is required for adequate withdrawal suppression in the absence of other opioids. But effective opioid blockade just needs higher receptor occupancy levels. Specifically, the effects of other opioids diminish greatly at the time 70% or more of mu-opioid receptors are occupied by buprenorphine. Studies demonstrate that a 16 mg dose of sublingual buprenorphine proved more effective than an 8 mg dose in blocking heroin’s reinforcing effects.
Preventing the Rewarding Effects of Other Opioids
Buprenorphine reduces both negative reinforcing and rewarding effects associated with other opioids, including euphoria and drug-liking sensations. Sublocade blocks these receptors from experiencing stronger euphoric highs if you take illicit opioids by occupying mu receptors. The medication can reduce cravings and block the rewarding effects of other opioids. This helps break the addiction cycle.
This blocking action prevents opioid-induced euphoria and also alleviates central nervous system and respiratory depressant effects. The protective mechanism operates because buprenorphine binds more tightly to mu-opioid receptors than most other opioids like fentanyl or heroin.
What Happens if You Take Opioids While on Sublocade
Taking illicit opioids while on Sublocade results in blunted effects. You will most likely not experience a high from the opioid because buprenorphine partially blocks mu-opioid receptors in your brain. Full opioids taken within 24 hours of a buprenorphine dose will not work. Blocking effects may persist up to 72 hours if you have some individuals.
Mixing opioids with Sublocade remains dangerous though. All opioids function as central nervous system depressants, and overdose can still occur even without feeling high. The blocking effect makes it difficult to feel full effects of other opioids, yet these substances still affect your body. Overdose risk increases because you might consume more of a substance than your body can handle while seeking effects that buprenorphine blocks.
The Duration of Opioid-Blocking Effects
Sublocade maintains blocking effects much longer than daily medications. The medication can remain in your system for months or years following administration. Buprenorphine stays in your bloodstream between 43 and 60 days, with traces detectable in urine for 22 to 38 months. This extended presence provides continuous month-long protection through sustained medicine levels without daily fluctuations.
Sublocade vs Suboxone: Blocking Properties Compared
Both Sublocade and Suboxone share buprenorphine as their therapeutic component, yet their formulations differ in one most important aspect. Suboxone combines buprenorphine with naloxone, while Sublocade relies on buprenorphine alone. This compositional difference raises questions about whether Sublocade has a blocker equal to Suboxone’s dual-ingredient approach.
Why Suboxone Contains Naloxone as a Blocker
Naloxone serves as a misuse deterrent rather than a therapeutic ingredient in Suboxone. Take Suboxone sublingually as prescribed and naloxone demonstrates less than 10% bioavailability and sublingual absorption rate compared to buprenorphine. Your body doesn’t absorb it, and you experience only buprenorphine’s therapeutic effects. But if someone attempts to inject or snort Suboxone, naloxone becomes active and binds to opioid receptors, preventing euphoria. This misuse triggers precipitated withdrawal with symptoms that include sweating, muscle pain, insomnia and agitation.
Naloxone’s presence creates an aversion technology that discourages parenteral administration. This mechanism represents a safety feature designed for take-home medications rather than a blocking boost.
Sublocade’s Single-Ingredient Formulation
Sublocade eliminates naloxone because healthcare professionals administer it in clinical settings through the REMS program. The monthly injection format prevents diversion opportunities associated with daily oral medications. The subcutaneous delivery method also makes intravenous misuse impractical and removes the primary concern that naloxone addresses in Suboxone formulations.
Which Medication Provides Better Opioid Blocking?
Both medications block opioid receptors through buprenorphine in a similar way. All buprenorphine medications block opioid receptors in like manner, whether they contain naloxone or not. Buprenorphine’s pharmacologic properties cause precipitated withdrawal if taken too soon after full opioids, with or without naloxone present. Buprenorphine’s high affinity for receptors means it adheres like adhesive and blocks other opioids whatever the naloxone.
Research shows the presence or absence of naloxone makes little practical difference in blocking effectiveness. Naloxone may reduce or delay subjective euphoria at best, but this partial blockade offers dubious clinical value to prevent misuse. Neither medication provides superior opioid blocking since buprenorphine performs this function in both formulations.
Clinical Benefits of Sublocade’s Opioid-Blocking Mechanism
The therapeutic advantages of Sublocade extend beyond simple opioid blocking and include detailed recovery support. Buprenorphine’s mechanism addresses multiple facets of opioid use disorder treatment through sustained receptor occupation.
Reducing Cravings and Withdrawal Symptoms
Sublocade delivers controlled buprenorphine amounts over one month and reduces cravings while blocking rewarding effects of other opioids. This continuous delivery helps patients break the addiction cycle. It manages to keep stable therapeutic levels without daily fluctuations. Clinical trials showed that 28% of patients on Sublocade plus counseling achieved treatment success compared to 2% on placebo plus counseling.
Mean Clinical Opioid Withdrawal Scale and Subjective Opioid Withdrawal Scale scores remained low at baseline and week 24 in treatment groups. Regarding desire-to-use Visual Analog Scale scores, final mean scores in the placebo group at week 24 reached 17.1. This was substantially higher than active treatment groups where scores measured 6.8 in the 300 mg/100 mg group and 3.2 in the 300 mg/300 mg group. Buprenorphine suppresses withdrawal symptoms and reduces cravings. Patients can focus on therapy rather than endure uncomfortable withdrawals.
Preventing Relapse During Recovery
Sublocade helps reduce illicit opioid use and interrupt the addiction cycle. Both dosage regimens showed mean percentage abstinence rates substantially higher than placebo, with 41.3% for 300/300 mg and 42.7% for 300/100 mg compared to 5.0% for placebo. Treatment success rates, defined as patients achieving 80% or more opioid-free weeks, reached 29.1% for 300/300 mg and 28.4% for 300/100 mg versus 2.0% for placebo.
After 18 months, 92.7% of newly initiated patients and 81.8% of rollover patients tested urine negative for opioids. Among early nonresponders with abstinence rates of 20% or lower, 73.1% were urine negative after 18 months.
Long-Acting Protection with Monthly Injections
Monthly administration will give consistent medication delivery without daily dosing burdens. Steady state is achieved after 4-6 monthly injections. Model simulations show that steady-state buprenorphine plasma concentrations decrease slowly following the last injection. Therapeutic levels are managed to keep for 2 to 5 months on average depending on dosage.
Safety Considerations and Supervised Administration
Certified healthcare providers administer Sublocade through the REMS Program exclusively. Patients are monitored in healthcare settings after injection to assess worsening withdrawal or sedation symptoms. Practitioners should strongly think over prescribing naloxone to treat emergency opioid overdose.
Conclusion
Sublocade blocks other opioids through buprenorphine alone effectively, without requiring naloxone as an additional blocker. The medication’s high receptor affinity and partial agonist properties create a protective barrier against other opioids while reducing cravings and withdrawal symptoms. You benefit from month-long protection through sustained therapeutic levels that help prevent relapse during recovery.
The monthly injection format eliminates daily dosing challenges and will give consistent medication delivery under professional supervision. You can focus on counseling and psychosocial support rather than managing daily medications. Buprenorphine’s unique mechanism demonstrates that opioid blocking depends on receptor binding characteristics rather than combination formulations. This makes Sublocade a valuable treatment option for opioid use disorder.